1 型糖尿病的免疫疗法：为何现行方案无法阻止潜在疾病进程？
Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
机构信息
West-German Centre of Diabetes and Health, Düsseldorf Catholic Hospital Group, Hohensandweg 37, 40591 Düsseldorf, Germany; Faculty of Medicine, University of Düsseldorf, 40225 Düsseldorf, Germany.
Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA; Novo Nordisk Diabetes Research and Development Center, Seattle, WA 98191, USA.
出版信息
Cell Metab. 2017 Feb 7;25(2):233-241. doi: 10.1016/j.cmet.2016.10.009. Epub 2016 Nov 10.
T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.
T 细胞定向免疫抑制仅能暂时延缓近期发生的 1 型糖尿病中β细胞功能的丧失。我们在此认为，潜在的疾病过程是由固有免疫反应引起的。诱导局部固有免疫的非极化功能状态将支持调节性 T 细胞的发育和β细胞的增殖。
Zotero 插件